PE20150732A1 - Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso - Google Patents

Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso

Info

Publication number
PE20150732A1
PE20150732A1 PE2015000270A PE2015000270A PE20150732A1 PE 20150732 A1 PE20150732 A1 PE 20150732A1 PE 2015000270 A PE2015000270 A PE 2015000270A PE 2015000270 A PE2015000270 A PE 2015000270A PE 20150732 A1 PE20150732 A1 PE 20150732A1
Authority
PE
Peru
Prior art keywords
minoxidil
finasteride
pharmaceutical composition
nanoparticula
polymeric
Prior art date
Application number
PE2015000270A
Other languages
English (en)
Inventor
Adriana Raffin Pohlmann
Ludmila Pinheiro Do Nascimento
Silvia Stanis�Uaski Guterres
Denise Soledade Jornada
Original Assignee
Biolab Sanus Farmac�Utica Ltda
Univ Fed Do Rio Grande Do Sul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50182296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150732(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biolab Sanus Farmac�Utica Ltda, Univ Fed Do Rio Grande Do Sul filed Critical Biolab Sanus Farmac�Utica Ltda
Publication of PE20150732A1 publication Critical patent/PE20150732A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La invencion se refiere a una composicion farmaceutica, de vehiculacion topica, para el tratamiento de la alopecia, dicha composicion comprende nanoparticulas polimericas, preferentemente nanocapsoides, conteniendo dos principios activos, finasterida y minoxidil, aditivos y vehiculo farmaceuticamente aceptables. La invencion ademas incluye un proceso de preparacion de las nanoparticulas polimercias, preferentemente nanocapsoides de finasterida y minoxidil, apropiadas para una composicion de vehiculacion topica para el tratamiento de la alopecia, asi como el uso de dichos nanocapsoides para la preparacion de una composicion farmaceutica
PE2015000270A 2012-08-31 2013-08-30 Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso PE20150732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102012022036-9A BR102012022036B1 (pt) 2012-08-31 2012-08-31 Nanopartícula polimérica de finasterida e minoxidil, processo de sua preparação, suspensão aquosa contendo a mesma, composição farmacêutica, e seu uso

Publications (1)

Publication Number Publication Date
PE20150732A1 true PE20150732A1 (es) 2015-05-17

Family

ID=50182296

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015000270A PE20150732A1 (es) 2012-08-31 2013-08-30 Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
PE2019001935A PE20191714A1 (es) 2012-08-31 2013-08-30 Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2019001935A PE20191714A1 (es) 2012-08-31 2013-08-30 Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso

Country Status (23)

Country Link
US (1) US9687554B2 (es)
EP (1) EP2891486B1 (es)
JP (1) JP6352265B2 (es)
KR (1) KR102118582B1 (es)
CN (1) CN104755075B (es)
AR (1) AR092403A1 (es)
AU (1) AU2013308356B2 (es)
BR (1) BR102012022036B1 (es)
CA (1) CA2883998C (es)
CL (1) CL2015000501A1 (es)
CO (1) CO7310520A2 (es)
DK (1) DK2891486T3 (es)
ES (1) ES2683418T3 (es)
IN (1) IN2015DN01728A (es)
MX (1) MX363961B (es)
MY (1) MY174692A (es)
PE (2) PE20150732A1 (es)
SA (1) SA515360084B1 (es)
TR (1) TR201810389T4 (es)
UA (1) UA113774C2 (es)
UY (1) UY35002A (es)
WO (1) WO2014032152A1 (es)
ZA (1) ZA201501255B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150174254A1 (en) * 2013-12-23 2015-06-25 Mcneil-Ppc, Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US9675537B2 (en) * 2014-06-30 2017-06-13 Johnson & Johnson Consumer Inc. Hair growth composition and method
CN104887685A (zh) * 2015-05-05 2015-09-09 谢秉权 一种治疗和/或预防男性型脱发的复方外用药
ES2613888B1 (es) * 2016-08-19 2017-11-16 Enrique Blanxart Sena Composición farmacéutica para el tratamiento de la alopecia
WO2018206077A1 (en) * 2017-05-08 2018-11-15 Merz Pharma Gmbh & Co. Kgaa Emulsion comprising finasteride
DK3638198T3 (da) * 2017-06-16 2021-11-22 Capilli Med Gmbh Sammensætning til at forebygge hårtab og fremme hårvækst
MX2018001546A (es) * 2018-02-06 2019-08-07 Centro Int De Cosmiatria S A P I De C V Formulacion y metodo para el tratamiento de la alopecia androgenica.
CN110448525A (zh) * 2018-05-08 2019-11-15 无锡派列博生物医药科技有限公司 一种预防脱发和促生发的外用非那雄胺脂质纳米制剂及其制备方法
WO2020097284A1 (en) * 2018-11-08 2020-05-14 Jindal Vinay K TOPICAL FORMULATIONS OF 5-α-REDUCTASE INHIBITORS AND USES THEREOF
WO2020121329A1 (en) * 2018-12-11 2020-06-18 Dr Rathod Sudha Suresh Minoxidil and castor oil nanoemulgel for alopecia
CN112773776B (zh) * 2019-11-11 2023-06-20 上海胜联医药科技有限公司 一种载药纳米粒体系
CN111329832B (zh) * 2020-02-08 2021-07-16 中山大学 一种治疗脱发的纳米脂质载体微针及其应用
EP4114362A4 (en) * 2020-03-05 2024-03-20 Univ Miami NANODRUG FORMULATIONS OF CANNABIDIOL AND THEIR METHODS OF USE
AU2020389480A1 (en) 2020-03-30 2021-10-14 Hyundaibioscience Co.,Ltd. Ethosomal composition including ethosomes encapsulating vitamin and dexpanthenol and method for preparing the same
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
CN114910567B (zh) * 2021-02-07 2023-11-24 株洲千金药业股份有限公司 一种检测非那雄胺中遗传毒性杂质的方法及其应用
CN113425845B (zh) * 2021-08-10 2022-12-02 成都倍特药业股份有限公司 一种预防和/或治疗脱发症的传递体制剂及其制备方法和用途
CN113797208B (zh) * 2021-11-17 2022-02-25 山东谷雨春生物科技有限公司 一种含米诺地尔的制剂及其制备方法和应用
KR20230113871A (ko) 2022-01-24 2023-08-01 (주) 해피론이엔지 발포폴리에틸렌메시를 이용한 건축물 층간소음방지 시공방법 및 구조.
KR102623083B1 (ko) 2022-05-02 2024-01-10 (주) 해피론이엔지 공명공간을 제거한 1차 몰탈 타설식 소음방지 시공공법 및 시공구조
CN115006712B (zh) * 2022-06-28 2024-01-09 广州汇元医药科技有限公司 一种米诺地尔的脂质纳米粒微针及其制备方法和应用
CN115252549B (zh) * 2022-07-12 2023-09-08 科辉智药生物科技（无锡）有限公司 提高生发活性物质药效的组合物及其制备方法
CN115400085A (zh) * 2022-09-02 2022-11-29 南昌大学 一种非那雄胺类脂囊泡及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
EP1154783A4 (en) * 1999-07-06 2005-01-19 Raziel Lurie RELAXIN-CONTAINING MEDICAMENTS AND ITS USE
KR100463167B1 (ko) * 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
CN100539988C (zh) * 2003-06-27 2009-09-16 株式会社太平洋 含有生理活性成分的自聚集聚合物纳米颗粒和含有该纳米颗粒的外用搽剂
WO2005000258A1 (en) 2003-06-27 2005-01-06 Amorepacific Corporation Self-assembled polymeric nanoparticles containing physiologically active ingredients and external application containing the nanoparticles
JP4939936B2 (ja) * 2003-06-27 2012-05-30 株式會社アモーレパシフィック 生理活性成分を含有する自己集合性高分子ナノ粒子の製造方法、及び得られた自己集合性高分子ナノ粒子を含有する外用剤組成物
WO2006099121A2 (en) 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
CN101500937A (zh) * 2006-08-11 2009-08-05 万能药生物有限公司 用于递送活性成分的粒子及其制备方法和组合物
US20080175807A1 (en) 2007-01-24 2008-07-24 Fujifilm Corporation Composition for hair
BRPI0700832B8 (pt) * 2007-03-16 2021-05-25 Biolab Sanus Farmaceutica Ltda composição anestésica tópica compreendendo suspensão de nanocápsulas poliméricas de lidocaína e prilocaína
WO2009058135A1 (en) * 2007-10-30 2009-05-07 Celonova Biosciences, Inc. Loadable polymeric microparticles for therapeutic use in alopecia and methods of preparing and using the same
LT2344198T (lt) 2008-09-27 2021-02-25 Jina Pharmaceuticals Inc. Farmaciniai preparatai lipidų pagrindu, skirti vietiniam naudojimui
WO2011031990A1 (en) * 2009-09-11 2011-03-17 Follica, Inc. Intermittent and pulse lithium treatments for modulating hair growth
ES2384060B1 (es) * 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos

Also Published As

Publication number Publication date
MX363961B (es) 2019-04-09
CA2883998C (en) 2020-08-25
CN104755075A (zh) 2015-07-01
MY174692A (en) 2020-05-07
KR20150044029A (ko) 2015-04-23
EP2891486A1 (en) 2015-07-08
BR102012022036A2 (pt) 2014-11-25
ES2683418T3 (es) 2018-09-26
AR092403A1 (es) 2015-04-22
CN104755075B (zh) 2019-07-26
IN2015DN01728A (es) 2015-05-29
US9687554B2 (en) 2017-06-27
JP2015526484A (ja) 2015-09-10
CO7310520A2 (es) 2015-06-30
US20150216986A1 (en) 2015-08-06
KR102118582B1 (ko) 2020-06-04
AU2013308356A1 (en) 2015-04-16
JP6352265B2 (ja) 2018-07-04
MX2015002300A (es) 2016-02-10
EP2891486B1 (en) 2018-05-16
UY35002A (es) 2014-03-31
EP2891486A4 (en) 2016-03-23
UA113774C2 (xx) 2017-03-10
CL2015000501A1 (es) 2015-07-03
WO2014032152A1 (pt) 2014-03-06
PE20191714A1 (es) 2019-12-05
CA2883998A1 (en) 2014-03-06
DK2891486T3 (en) 2018-07-23
BR102012022036B1 (pt) 2019-10-01
ZA201501255B (en) 2016-01-27
TR201810389T4 (tr) 2018-08-27
AU2013308356B2 (en) 2017-09-28
SA515360084B1 (ar) 2016-10-03

Similar Documents

Publication Publication Date Title
PE20150732A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
PE20150731A1 (es) Nanoparticula polimerica de finasterida, suspension acuosa conteniendo a la misma, composicion para tratamiento de alopecia, proceso de preparacion de dicha composicion, y su uso
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
EA201590215A1 (ru) Макроциклические пурины для лечения вирусных инфекций
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
CL2013000250A1 (es) Compuestos conjugados de dimeros de pirrolo[1,4]benzodiazepina; procedimiento de preparacion; y su uso como agente anticanceroso.
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
SG10201804817TA (en) Delayed release compositions of linaclotide
PH12015502118A1 (en) Pyridin-4-yl derivatives
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
PH12014502465A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
MX2015017541A (es) Derivados de espiro [2.4] heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx.
CL2011001904A1 (es) Formulacion farmaceutica que comprende celulas madres mesenquimales vivas suspendidas en un vehiculo farmaceuticamente aceptable, sistema de aplicacion topica en aerosol que las comprende; y su uso para tratar heridas.
AR094224A1 (es) Composicion farmaceutica en forma de una suspension oral
CY1122538T1 (el) Συμπλεγματα χονδροϊτινης για διαδερμικη απορροφηση
EA201400609A1 (ru) Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
EA201400444A1 (ru) Производные 2-оксопиперидинила
CL2015001500A1 (es) Composicion en suspensión topica de finafloxacina; metodo de preparacion y uso para el tratamiento de una infeccion oftalmica, otica o nasal.
IN2015DN02660A (es)
TR201203083A2 (tr) Sefdinir ve klavulanik asit içeren farmasötik dozaj formu.
TR201203085A2 (tr) Sefetamet ve klavulanik asit içeren bileşimler.

Legal Events

Date Code Title Description
FC Refusal